K药头对头:三生制药启动PD-1/VEGF双抗首个三期临床

药渡
May 23, 2025

▎Armstrong2025年5月20日,三生制药在Clinicaltrials.gov网站上注册了PD-1/VEGF双抗一线治疗晚期非小细胞肺癌(NSCLC)的三期临床试验,这也是SSGJ-707首个三期临床。该三期临床计划入组420例晚期PD-L1阳性、局部晚期或转移性非小细胞肺癌(NSCLC)患者,SSGJ-707单药治疗头对头对比Keytruda,预计2026年7月初步完成。同样在昨天,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10